95 related articles for article (PubMed ID: 30069762)
1. Trametinib (GSK1120212).
Zeiser R; Andrlová H; Meiss F
Recent Results Cancer Res; 2018; 211():91-100. PubMed ID: 30069762
[TBL] [Abstract][Full Text] [Related]
2. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract][Full Text] [Related]
3. New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.
Brighton HE; Angus SP; Bo T; Roques J; Tagliatela AC; Darr DB; Karagoz K; Sciaky N; Gatza ML; Sharpless NE; Johnson GL; Bear JE
Cancer Res; 2018 Jan; 78(2):542-557. PubMed ID: 29180473
[TBL] [Abstract][Full Text] [Related]
4. β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models.
Ganesh S; Shui X; Craig KP; Koser ML; Chopda GR; Cyr WA; Lai C; Dudek H; Wang W; Brown BD; Abrams MT
Mol Cancer Ther; 2018 Feb; 17(2):544-553. PubMed ID: 29282298
[TBL] [Abstract][Full Text] [Related]
5. Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies.
De Carli A; Kapelyukh Y; Kursawe J; Chaplain MAJ; Wolf CR; Hamis S
NPJ Syst Biol Appl; 2024 May; 10(1):51. PubMed ID: 38750040
[TBL] [Abstract][Full Text] [Related]
6. MEK and the inhibitors: from bench to bedside.
Akinleye A; Furqan M; Mukhi N; Ravella P; Liu D
J Hematol Oncol; 2013 Apr; 6():27. PubMed ID: 23587417
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib.
Kim J; Lee TS; Lee MH; Cho IR; Ryu JK; Kim YT; Lee SH; Paik WH
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473413
[TBL] [Abstract][Full Text] [Related]
8. The purpose of repurposing.
Barrett JE; Kim FJ
Oncotarget; 2017 Feb; 8(8):12534-12535. PubMed ID: 28129642
[No Abstract] [Full Text] [Related]
9. Opportunities for targeted therapies: trametinib as a therapeutic approach to canine oral squamous cell carcinomas.
Peralta S; Katt W; Balkman C; Butler S; Carney P; Todd-Donato A; Drozd M; Duhamel G; Fiani N; Ford J; Grenier J; Hayward J; Heikinheimo K; Hume K; Moore E; Puri R; Sylvester S; Warshaw S; Webb S; White A; Wright A; Cerione R
Res Sq; 2024 May; ():. PubMed ID: 38746473
[TBL] [Abstract][Full Text] [Related]
10. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.
Lian T; Li C; Wang H
Cancer Treat Rev; 2019 Dec; 81():101907. PubMed ID: 31715422
[TBL] [Abstract][Full Text] [Related]
11. Cobimetinib (GDC-0973, XL518).
Andrlová H; Zeiser R; Meiss F
Recent Results Cancer Res; 2018; 211():177-186. PubMed ID: 30069767
[TBL] [Abstract][Full Text] [Related]
12. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
[TBL] [Abstract][Full Text] [Related]
13. Trametinib: A Targeted Therapy in Metastatic Melanoma.
Hoffner B; Benchich K
J Adv Pract Oncol; 2018; 9(7):741-745. PubMed ID: 31249721
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.
Puszkiel A; Noé G; Bellesoeur A; Kramkimel N; Paludetto MN; Thomas-Schoemann A; Vidal M; Goldwasser F; Chatelut E; Blanchet B
Clin Pharmacokinet; 2019 Apr; 58(4):451-467. PubMed ID: 30094711
[TBL] [Abstract][Full Text] [Related]
15. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.
Jeanson A; Boyer A; Greillier L; Tomasini P; Barlesi F
Expert Rev Anticancer Ther; 2019 Jan; 19(1):11-17. PubMed ID: 30513023
[No Abstract] [Full Text] [Related]
17. Trametinib for progressive pediatric low-grade gliomas.
Kondyli M; Larouche V; Saint-Martin C; Ellezam B; Pouliot L; Sinnett D; Legault G; Crevier L; Weil A; Farmer JP; Jabado N; Perreault S
J Neurooncol; 2018 Nov; 140(2):435-444. PubMed ID: 30097824
[TBL] [Abstract][Full Text] [Related]
18. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.
Degirmenci U; Wang M; Hu J
Cells; 2020 Jan; 9(1):. PubMed ID: 31941155
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the action of the drug trametinib at KSR-bound MEK.
Khan ZM; Real AM; Marsiglia WM; Chow A; Duffy ME; Yerabolu JR; Scopton AP; Dar AC
Nature; 2020 Dec; 588(7838):509-514. PubMed ID: 32927473
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
